CU20200035A7 - Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2 - Google Patents

Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2

Info

Publication number
CU20200035A7
CU20200035A7 CU2020000035A CU20200035A CU20200035A7 CU 20200035 A7 CU20200035 A7 CU 20200035A7 CU 2020000035 A CU2020000035 A CU 2020000035A CU 20200035 A CU20200035 A CU 20200035A CU 20200035 A7 CU20200035 A7 CU 20200035A7
Authority
CU
Cuba
Prior art keywords
dihydro
oxo
alk
pyridin
substituted
Prior art date
Application number
CU2020000035A
Other languages
English (en)
Inventor
Luca Arista
Sylvie Chamoin
Pier Luca D´Alessandro
Mika Lindvall
Dimitrios Lizos
Nikolaus Johannes Stiefl
Sylvie Teixeira-Fouchard
Thomas Ullrich
Sven Weiler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20200035A7 publication Critical patent/CU20200035A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

<p>La invención se refiere a compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos de Fórmula I,</p> <p>ESPACIO PARA FÓRMULA</p> <p>útiles como inhibidores selectivos de ALK-2.</p>
CU2020000035A 2017-11-24 2017-11-24 Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2 CU20200035A7 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2017/057389 WO2019102256A1 (en) 2017-11-24 2017-11-24 Pyridinone derivatives and their use as selective alk-2 inhibitors

Publications (1)

Publication Number Publication Date
CU20200035A7 true CU20200035A7 (es) 2021-03-11

Family

ID=60702886

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000035A CU20200035A7 (es) 2017-11-24 2017-11-24 Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2

Country Status (24)

Country Link
US (1) US11160797B2 (es)
EP (1) EP3713927B1 (es)
JP (1) JP7091455B2 (es)
KR (1) KR20200091422A (es)
CN (1) CN111433195B (es)
AU (1) AU2017440306B2 (es)
BR (1) BR112020010171A2 (es)
CA (1) CA3081651A1 (es)
CL (1) CL2020001277A1 (es)
CO (1) CO2020005885A2 (es)
CR (1) CR20200211A (es)
CU (1) CU20200035A7 (es)
DO (1) DOP2020000088A (es)
EA (1) EA202091293A1 (es)
EC (1) ECSP20026023A (es)
ES (1) ES2908252T3 (es)
IL (1) IL274722A (es)
JO (1) JOP20200127A1 (es)
MX (1) MX2020005405A (es)
PE (1) PE20201282A1 (es)
PH (1) PH12020550763A1 (es)
RU (1) RU2020120538A (es)
SG (1) SG11202003920QA (es)
WO (1) WO2019102256A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7504880B2 (ja) 2018-10-26 2024-06-24 ケロス セラピューティクス インコーポレイテッド Ａｌｋ２阻害剤の結晶形
WO2021222875A1 (en) * 2020-04-30 2021-11-04 Keros Therapeutics, Inc. Methods of using alk2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CN113354631B (zh) * 2021-06-01 2022-11-18 江苏大学 一种1,3,4-噁二唑衍生物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2149441C (en) 1992-11-17 2004-03-02 Kohei Miyazono Activin receptor-like kinases, proteins having serine threonine kinase domains and their use
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US8895711B2 (en) 2006-04-18 2014-11-25 The Trustees Of The University Of Pennsylvania Mutated ACVR1 for diagnosis and treatment of Fibrodyplasia Ossificans Progressiva (FOP)
EA200970250A1 (ru) 2006-09-05 2010-02-26 Медарекс, Инк. Антитела к костным морфогенетическим белкам и их рецепторам и способы их применения
JP2010503383A (ja) 2006-09-12 2010-02-04 ザ ジェネラル ホスピタル コーポレイション 細胞シグナリングをモジュレートする化合物を同定するための方法およびこのような化合物を使用する方法
JP5638961B2 (ja) 2008-03-13 2014-12-10 ザ ジェネラル ホスピタル コーポレイション Ｂｍｐシグナル伝達経路のインヒビター
CN110818724B (zh) * 2010-05-07 2020-11-13 吉利德康涅狄格有限公司 吡啶酮和氮杂吡啶酮化合物及使用方法
CN103079585B (zh) 2010-08-20 2015-09-30 惠氏有限责任公司 经设计的成骨蛋白
CA2819955A1 (en) 2010-12-06 2012-06-14 Piramal Enterprises Limited Substituted imidazoquinoline derivatives
DK3321262T3 (da) 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
EP3122355A4 (en) * 2014-03-26 2017-08-09 The Brigham and Women's Hospital, Inc. Compositions and methods for inhibiting bmp
WO2016054406A1 (en) * 2014-10-01 2016-04-07 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting bmp
AU2016249537B2 (en) * 2015-04-16 2020-01-30 Merck Patent Gmbh 3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one derivatives

Also Published As

Publication number Publication date
IL274722A (en) 2020-07-30
EA202091293A1 (ru) 2020-11-23
ES2908252T3 (es) 2022-04-28
CO2020005885A2 (es) 2020-07-31
JOP20200127A1 (ar) 2020-05-21
RU2020120538A (ru) 2021-12-24
SG11202003920QA (en) 2020-06-29
CN111433195B (zh) 2023-04-25
AU2017440306B2 (en) 2021-01-28
ECSP20026023A (es) 2020-07-31
PH12020550763A1 (en) 2021-04-26
CL2020001277A1 (es) 2020-11-13
JP7091455B2 (ja) 2022-06-27
DOP2020000088A (es) 2020-08-31
US20200360357A1 (en) 2020-11-19
WO2019102256A1 (en) 2019-05-31
BR112020010171A2 (pt) 2020-11-03
KR20200091422A (ko) 2020-07-30
MX2020005405A (es) 2020-08-13
AU2017440306A1 (en) 2020-05-21
US11160797B2 (en) 2021-11-02
RU2020120538A3 (es) 2021-12-24
CN111433195A (zh) 2020-07-17
CA3081651A1 (en) 2019-05-31
EP3713927A1 (en) 2020-09-30
PE20201282A1 (es) 2020-11-24
EP3713927B1 (en) 2021-12-15
JP2021512850A (ja) 2021-05-20
CR20200211A (es) 2020-06-19

Similar Documents

Publication Publication Date Title
CO2018013105A2 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2017002155A1 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
CU20180001A7 (es) Derivados de oxopiridina sustituidos y procesos para su preparación
MX2018002986A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y sus usos.
MX2018006148A (es) Inhibidores de cxcr2.
MX2018003130A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos.
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
MX2019013645A (es) Inhibidores de quinasa y usos de los mismos.
MX377277B (es) Derivados de fenoximetilo.
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
CU20200051A7 (es) Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
EA201792021A1 (ru) Ингибитор jak
CR20140229A (es) Nuevos derivados bicíclicos de dihidroisoquinolin-1-ona
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
MX394835B (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
NZ742952A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
CU20200035A7 (es) Compuestos derivados de piridin-2-ona (6´-oxo-1´,6´dihidro) sustituidos como inhibidores selectivos de alk-2
CU20200108A7 (es) Derivados de espirocromano como moduladores del receptor de acetilcolina nicotínica alfa7
CL2020000376A1 (es) Compuesto pentacíclico.
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CU24518B1 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina
CR20170058A (es) Un derivado de tetrahidropirrolo[3,4-d][1,3]tiazina como inhibidor de bace
EA201791098A1 (ru) Способ синтеза производных бензазепина
PY1735113A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
IN2013CH05394A (es)